Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Germany's Robert Koch Institute (RKI) for infectious diseases has declared the country's RSV wave officially over. RSV, or ...

Each year, approximately 177,000 adults aged 65 and older are hospitalized in the United States due to RSV, and an estimated ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Though they may be fit and healthy, older adults should know the risks of respiratory illness and how to protect themselves.

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Taiwan: Patients with obstructive sleep apnea (OSA) may face a significantly increased risk of contracting respiratory ...

A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...